Fed’s "dot plot" seen projecting three rate cuts by the end of 2025 - Barclays
Investing.com - H.C. Wainwright has reiterated its Buy rating and $9.00 price target on Lineage Cell Therapeutics Inc. (NYSE:LCTX), a $283 million market cap biotech company whose shares have surged 136% over the past six months. The rating reaffirmation follows the company’s announcement of a new initiative in Type 1 diabetes treatment. According to InvestingPro data, the stock is currently trading near its 52-week high of $1.31.
The company revealed on September 8 its plans to develop a new islet cell transplant program for Type 1 diabetes, leveraging its extensive experience in embryonic and other cell line manipulation.
H.C. Wainwright noted that while the initiative is in its early stages, it could significantly impact hypoimmune cell development, potentially leading to functional cures based on early data from islet and beta cell approaches.
The research firm identified manufacturing as a critical challenge for the program, specifically highlighting the difficulty in achieving stable and massive volumes of cells needed for commercial viability.
Despite these challenges, H.C. Wainwright maintained its positive outlook on Lineage Cell Therapeutics, keeping both its Buy rating and $9.00 price target unchanged. The company has demonstrated strong revenue growth of 76% in the last twelve months, though InvestingPro analysis indicates challenges ahead with expected earnings decline this year. For deeper insights into LCTX’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Lineage Cell Therapeutics reported a significant increase in revenue for the second quarter of 2025, reaching $2.8 million, which exceeded analyst expectations. Despite the revenue boost, the company experienced a net loss of $0.13 per share, which was wider than anticipated by analysts. In addition to the earnings report, Lineage Cell Therapeutics announced a research collaboration with William Demant Invest A/S to advance the development of ReSonance, a cell therapy targeting hearing loss. Under this agreement, William Demant will provide up to $12 million over three years to support preclinical development activities. This partnership will focus on cell manufacturing, proof-of-concept studies, delivery development, and regulatory strategy. These recent developments indicate a strategic focus on both financial performance and therapeutic advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.